Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Australian Clinical Labs Limited (**ACL**)
ABN	94 645 711 128

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melinda McGrath
Date of last notice	14 May 2021

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	A.C.N. 633 176 100 Pty Ltd (ACN 633 176 100) as trustee for the McGrath Family Trust is the registered holder of 667,965 ordinary shares in ACL. Melinda McGrath is a director of A.C.N. 633 176 100 Pty Ltd and is a beneficiary of the McGrath Family Trust.
Date of change	25 May 2021
No. of securities held prior to change	2,791,473 ordinary shares, comprising of 2,123,508 ordinary shares held directly and 667,965 ordinary shares held indirectly.
Class	Performance rights (**Rights**) issued in accordance with the ACL long-term variable remuneration plan (**LTVR Plan**) in respect of the financial year ending 30 June 2022, as outlined in the prospectus lodged by ACL and ACL SaleCo Limited (ACN 648 177 646) with the Australian Securities and Investments Commission on 28 April 2021 (**Prospectus**).
Number acquired	247,252 Rights. The Rights will only vest in accordance with the provisions of the LTVR Plan.
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Rights were issued for nil consideration under the LTVR Plan. The number of Rights granted to Melinda McGrath under the LTVR Plan was determined via the application of the following formula: Maximum LTVR $ ÷ Value of the Right where Right value is equal to the Black-Scholes value of a Right (undiscounted for vesting conditions) based on the offer price of $4.00 per share under the Prospectus, which equated to $3.64.
No. of securities held after change	2,791,473 ordinary shares 247,252 Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Rights in accordance with the ACL LTVR Plan in respect of the financial year ending 30 June 2022, as outlined in the Prospectus.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder **(if issued securities)**	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A